Print

Featured Studies Results

ADHERE: Survey about Pancreatic Cancer Screening Options for People with Inherited Risk

https://www.facingourrisk.org/research-clinical-trials/study/368/adhere-survey-about-pancreatic-cancer-screening-options-for-people-with-inherited-risk

Surveys, Registries, Interviews
Online survey about pancreatic cancer screening for people with an inherited mutation in genes that are linked to an increased risk of pancreatic cancer

NePtune: Using PARP Inhibitors Before Surgery in Localized Prostate Cancer

https://www.facingourrisk.org/research-clinical-trials/study/314/neptune-using-parp-inhibitors-before-surgery-in-localized-prostate-cancer

Clinicaltrials.gov identifier:
NCT05498272 (https://clinicaltrials.gov/show/NCT05498272)

Treatment
Treatment study for people with intermediate- or high-risk prostate cancer with certain tumor mutations

Treating Advanced Cancers with BRCA or Other Related Gene Mutations Using Targeted Therapy MOMA-313 Alone or In Combination with the PARP Inhibitor Olaparib

https://www.facingourrisk.org/research-clinical-trials/study/328/treating-advanced-cancers-with-dna-repair-mutations-using-moma-313-alone-or-in-combination-with-the-parp-inhibitor-olaparib

Clinicaltrials.gov identifier:
NCT06545942 (https://clinicaltrials.gov/show/NCT06545942)

Treatment
Treatment study for people with advanced or metastatic cancers

Using a PARP Inhibitor and Oral Chemotherapy to Treat Advanced Solid Tumors with a Mutation in BRCA1, BRCA2, PALB2, ATM or CHEK2

https://www.facingourrisk.org/research-clinical-trials/study/376/using-a-parp-inhibitor-and-oral-chemotherapy-to-treat-advanced-solid-tumors-with-a-mutation-in-brca1-brca2-palb2-atm-or-chek2

Clinicaltrials.gov identifier:
NCT06177171 (https://clinicaltrials.gov/show/NCT06177171)

Treatment
Phase 1 treatment study for metastatic solid tumors

A New Targeted Therapy CX‑5461 to Treat Advanced Breast, Ovarian, Pancreatic or Prostate Cancer with an ATM, BRCA1/2, CHEK2, PALB2 or Other Mutation

https://www.facingourrisk.org/research-clinical-trials/study/377/an-new-targeted-therapy-cx5461-to-treat-advanced-breast-ovarian-pancreatic-or-prostate-cancer-with-inherited-or-tumor-mutations

Clinicaltrials.gov identifier:
NCT04890613 (https://clinicaltrials.gov/show/NCT04890613)

Treatment
Phase 1 treatment study for advanced or metastatic breast, ovarian, pancreatic or prostate cancer

Pancreatic Cancer Screening Study for People with ATM, BRCA1, BRCA2 or PALB2 Mutations

https://www.facingourrisk.org/research-clinical-trials/study/330/screening-study-for-pancreatic-cancer

Clinicaltrials.gov identifier:
NCT05058846 (https://clinicaltrials.gov/show/NCT05058846)

Prevention
Pancreatic cancer screening study for people with ATM, BRCA1, BRCA2 or PALB2 mutations

Studying a New PARP Inhibitor and Hormonal Therapy to Treat HER2-negative, HR-positive Metastatic Breast Cancer with a BRCA1, BRCA2, or PALB2 Mutation (EvoPAR BR01)

https://www.facingourrisk.org/research-clinical-trials/study/349/studying-a-new-parp-inhibitor-and-hormonal-therapy-to-treat-her2-negative-hr-positive-metastatic-breast-cancer-with-a-brca1-brca2-or-palb2-mutation-evopar-br01

Clinicaltrials.gov identifier:
NCT06380751 (https://clinicaltrials.gov/show/NCT06380751)

Treatment
Phase 3 treatment study for HER2-negative, HR-positive metastatic breast cancer with a BRCA1, BRCA2 or PALB2 mutation

HEAL-ABC Study: Harnessing E-Mindfulness Approaches for Living-After Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/342/heal-abc-study-harnessing-e-mindfulness-approaches-for-living-after-breast-cancer

Clinicaltrials.gov identifier:
NCT06748222 (https://clinicaltrials.gov/show/NCT06748222)

Quality of Life
Quality of life study for young breast cancer survivors who have symptoms associated with depression

Treating HER2-negative, Metastatic Breast Cancer with a BRCA or PALB2 Mutation Using a New Drug, Axatilimab, Combined with Olaparib

https://www.facingourrisk.org/research-clinical-trials/study/345/treating-her2-negative-brca12-or-palb2-positive-metastatic-breast-cancer-using-a-new-drug-combined-with-olaparib

Clinicaltrials.gov identifier:
NCT06488378 (https://clinicaltrials.gov/show/NCT06488378)

Treatment
Treatment study for HER2-negative, metastatic breast cancer with a BRCA1/2 or PALB2 mutation

Looking at Tumor DNA Before Chemotherapy to Predict Cancer Recurrence in People with High-Risk, Early-Stage Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/344/study-looking-at-tumor-dna-to-predict-cancer-recurrence-for-those-planning-to-undergo-chemotherapy-for-high-risk-early-breast-cancer

Clinicaltrials.gov identifier:
NCT06401421 (https://clinicaltrials.gov/show/NCT06401421)

Treatment
Biomarker study for people with early-stage breast cancer

Pancreatic Cancer Screening Study (CAPS5)

https://www.facingourrisk.org/research-clinical-trials/study/222/pancreatic-cancer-screening-studycaps5

Clinicaltrials.gov identifier:
NCT02000089 (https://clinicaltrials.gov/show/NCT02000089)

Prevention
Screening study for people at high risk for pancreatic cancer

Registry for People at Increased Risk for Pancreatic Cancer

https://www.facingourrisk.org/research-clinical-trials/study/331/registry-for-people-at-increased-risk-for-pancreatic-cancer

Clinicaltrials.gov identifier:
NCT06151223 (https://clinicaltrials.gov/show/NCT06151223)

Surveys, Registries, Interviews
Study collecting blood samples and imaging records of people at high risk of developing pancreatic cancer

Study of the Drug Olvi-Vec in Women with Ovarian Cancer

https://www.facingourrisk.org/research-clinical-trials/study/334/study-of-the-drug-olvi-vec-in-women-with-ovarian-cancer

Clinicaltrials.gov identifier:
NCT05281471 (https://clinicaltrials.gov/show/NCT05281471)

Treatment
Treatment for women diagnosed with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer or whose cancer did not respond to prior chemotherapy

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents (EvoPAR-PR01)

https://www.facingourrisk.org/research-clinical-trials/study/339/studying-the-effectiveness-of-new-parp-inhibitor-saruparib-compared-to-current-treatment-options-for-metastatic-prostate-cancer-evopar-pro1

Clinicaltrials.gov identifier:
NCT06120491 (https://clinicaltrials.gov/show/NCT06120491)

Treatment
Treatment study for metastatic, castration-sensitive prostate cancer

Understanding Risk Factors for Stomach Cancer in People with Inherited Mutations

https://www.facingourrisk.org/research-clinical-trials/study/332/understanding-risk-factors-for-stomach-cancer-in-people-with-inherited-mutations

Surveys, Registries, Interviews
Online survey on stomach cancer risk for people with an inherited mutation in genes that are linked to an increased risk of certain cancers

Understanding the Emotional and Social Experiences of Individuals Diagnosed with Ovarian Cancer

https://www.facingourrisk.org/research-clinical-trials/study/335/understanding-the-emotional-and-social-experiences-of-individuals-living-with-ovarian-cancer

Surveys, Registries, Interviews
Survey for people diagnosed with ovarian cancer

Cognitive Training for Breast Cancer Survivors with Memory and Thinking Problems

https://www.facingourrisk.org/research-clinical-trials/study/312/cognitive-training-for-breast-cancer-survivors-with-memory-and-thinking-problems

Clinicaltrials.gov identifier:
NCT05896189 (https://clinicaltrials.gov/show/NCT05896189)

Quality of Life
How well cognitive training helps breast cancer survivors with their memory and thinking problems

PATROL Study: Prostate Cancer Screening for People AT Genetic Risk FOr Aggressive Disease

https://www.facingourrisk.org/research-clinical-trials/study/291/patrol-study-prostate-cancer-screening-for-people-at-genetic-risk-for-aggressive-disease

Clinicaltrials.gov identifier:
NCT04472338 (https://clinicaltrials.gov/show/NCT04472338)

Prevention
Screening study for people with a mutation linked to prostate cancer risk

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.